心脉隆注射液对慢性心力衰竭患者的疗效和安全性研究  

Study on the Efficacy and Safety of Xinmailong Injection in Patients with Chronic Heart Failure

作　　者：陈华 周明龙[1] 任智敏[1] 朱海鹏[1] CHEN Hua;ZHOU Ming-long;REN Zhi-min;ZHU Hai-peng(Medical Cardiology,Rugao People's Hospital,Rugao 226500,China)

机构地区：[1]江苏省如皋市人民医院心内科,江苏如皋226500

出　　处：《药物生物技术》2021年第1期66-69,共4页Pharmaceutical Biotechnology

摘　　要：探讨心脉隆注射液治疗慢性心力衰竭患者的治疗有效性和安全性。选取该院心内科于2017年6月至2019年6月期间收治的64例慢性心力衰竭患者作为本次研究的对象,将其随机均分为治疗组(n=32)和安慰剂组(n=32)。心脉隆注射液组在标准治疗的基础上加入心脉隆注射液治疗(5 mg/kg,静脉滴注)。对照组采用标准治疗加等量注射磷酸盐缓冲盐水液安慰剂治疗。疗程均为7 d。使用《2018中国心力衰竭诊断和治疗指南》的心功能分级、左室射血分数、B型利钠肽、6 min步行距离等评估指标对不同治疗方式下患者的治疗效果进行评价与研究。研究结果显示心脉隆注射液组患者心功能分级和左室射血分数均显著优于对照组(P<0.01)。心脉隆注射液组患者治疗后B型利钠肽较对照组有明显降低(P<0.01);本次研究的整个过程中并未发生死亡事故,且两组发生不良事件的数量并无任何统计学差异(P>0.05)。心脉隆注射液对于缓解慢性心力衰竭患者的临床症状、改善心功能、运动耐量具有显著效果,且使用相对安全,具有可靠的临床应用价值。To evaluate the effectiveness and safety of Xinmailong injection in the treatment of patients with chronic heart failure,64 patients with chronic heart failure admitted to the cardiology department of this hospital from June 2017 to June 2019 were selected as the research objects,and they were randomly divided into the Xinmailong injection group( n = 32) and the control group( n = 32).Xinmailong injection group was treated with standard treatment plus Xinmailong injection( 5 mg/kg,intravenous drip).The control group was treated with standard treatment plus an equal injection of phosphate buffered saline solution placebo.The course of treatment was 7 days.Use the"2018 Chinese Heart Failure Diagnosis and Treatment Guidelines"cardiac function classification,left ventricular ejection fraction,B-type natriuretic peptide,and 6-min walking distance to evaluate the treatment effect.Patients in the Xinmailong injection group were better than those in the control group in terms of cardiac function classification and left ventricular ejection fraction according to the"2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure"( P<0.01).B-type natriuretic peptides were significantly different between the two groups after treatment( P<0.01).Compared with the control group,the Btype natriuretic peptides of patients in the Xinmailong injection group decreased after treatment( P<0.01).No deaths occurred during the study.There was no statistical difference in the number of adverse events between the two groups( P>0.05). Xinmailong injection could relieve the symptoms of patients with chronic heart failure,improved heart function,exercise tolerance,and was safe to use.

关 键 词：心脉隆注射液 慢性心力衰竭 B型利钠肽 心室射血分数 心功能 对照组 

分 类 号：R972[医药卫生—药品] R541[医药卫生—药学]